Top

Published in:

01-09-2015 | Case Report

A high-risk patient with long-QT syndrome with no response to cardioselective beta-blockers

Authors: Naoki Toyota, Aya Miyazaki, Heima Sakaguchi, Wataru Shimizu, Hideo Ohuchi

Published in: Heart and Vessels | Issue 5/2015

Abstract

We present a case of a high-risk 19-year-old female with long-QT syndrome (LQTS) with compound mutations. She had a history of aborted cardiac arrest and syncope and had received treatment with propranolol for 15 years. However, because she developed adult-onset asthma we tried to switch propranolol, a nonselective beta-blocker, to beta-1-cardioselective agents, bisoprolol and metoprolol. These resulted in both a markedly prolonged corrected QT interval and the development of LQTS-associated arrhythmias. Eventually, propranolol was reinitiated at a higher dose with the addition of verapamil, and she has had no further cardiac or asthmatic events for 5 years.

Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML (2000) Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101:616–623CrossRefPubMed

Goldenberg I, Bradley J, Moss A, Mcnitt S, Polonsky S, Robinson JL, Andrewa M, Zareba W (2010) Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol 21:893–901PubMedCentralPubMed

Goldenberg I, Moss AJ, Peterson DR, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Priori SG, Qi M, Schwartz PJ, Towbin JA, Vincent GM, Zhang L (2008) Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 117:2184–2191CrossRefPubMedCentralPubMed

Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, Heijden JF, Hauer RN, Beckmann BM, Spazzolini C, Rordorf R, Rydberg A, Clur SA, Fischer M, Heuvel F, Kaab S, Blom NA, Ackerman MJ, Schwartz PJ, Wilde AA (2012) Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2. J Am Coll Cardiol 60:2092–2099CrossRefPubMedCentralPubMed

Chatrath R, Bell CM, Ackerman MJ (2004) Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatr Cardiol 25:459–465CrossRefPubMed

Nakashima K, Kusakawa I, Yamamoto T, Hirabayashi S, Hosoya R, Shimizu W, Sumitomo N (2013) A left ventricular noncompaction in a patient with long QT syndrome caused by a KCNQ1 mutation: a case report. Heart Vessels 28:126–129CrossRefPubMed

Goldenberg I, Moss AJ (2008) Long QT syndrome. J Am Coll Cardiol 51:2291–2300CrossRefPubMed

Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R (2001) Genotype–phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103:89–95CrossRefPubMed

Itoh H, Shimizu W, Hayashi K, Yamagata K, Sakaguchi T, Ohno S, Makiyama T, Akao M, Ai T, Noda T, Miyazaki A, Miyamoto Y, Yamagishi M, Kamakura S, Horie M (2010) Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Heart Rhythm 7:1411–1418CrossRefPubMed

10.

Bando S, Soeki T, Matsuura T, Niki T, Ise T, Yamaguchi K, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Akaike M, Aiba T, Shimizu W, Sata M (2013) Congenital long QT syndrome with compound mutations in the KCNH2 gene. Heart Vessels. doi: 10.1007/s00380-013-0406-2

11.

Villain E, Denjoy I, Lupoglazoff JM, Guicheney P, Hainque B, Lucet V, Bonnet D (2004) Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J 25:1405–1411CrossRefPubMed

12.

Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, Crotti L, Piippo K, Lupoglazoff J, Villain E, Priori SG, Napolitano C, Zhang L (2009) High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. Circulation 119:215–221CrossRefPubMed

13.

Bankston JR, Kass RS (2010) Molecular determinants of local anesthetic action of beta-blocking drugs: implication for therapeutic management of long QT syndrome variant 3. J Mol Cell Cardiol 48:246–253CrossRefPubMedCentralPubMed

14.

Duff HJ, Mitchell LB, Wyse DG (1986) Antiarrhythmic efficacy of propranolol: comparison of low and high serum concentrations. J Am Coll Cardiol 8:959–965CrossRefPubMed

15.

Aygul N, Ozdemir K, Duzenli MA, Aygul MU (2009) The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. Cardiology 112:168–173CrossRefPubMed

16.

Viitasalo M, Oikarinen L, Swan H, Vaananen H, Jarvenpaa J, Hietanen H, Karjalainen J, Toivonen L (2006) Effects of beta-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome. J Am Coll Cardiol 48:747–753CrossRefPubMed

17.

Extramiana F, Maison-Blanche P, Denjoy I, Jode PD, Messali A, Labbe JP, Leenhardt A (2013) Gene-specific effect of beta-adrenergic blockade on corrected QT interval in the long QT syndrome. Ann Noninvasive Electrocardiol 18:399–408CrossRefPubMed

18.

Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, Qi M, Robinson JL (2010) Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol 55:783–788CrossRefPubMed

Title: A high-risk patient with long-QT syndrome with no response to cardioselective beta-blockers
Authors: Naoki Toyota
Aya Miyazaki
Heima Sakaguchi
Wataru Shimizu
Hideo Ohuchi
Publication date: 01-09-2015
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 5/2015
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-014-0530-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

A high-risk patient with long-QT syndrome with no response to cardioselective beta-blockers

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE−/− mice

Autoimmunity and pulmonary hypertension in patients with Graves’ disease

High incidence and severity of periodontitis in patients with Marfan syndrome in Japan

Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective percutaneous coronary intervention

Myocardial protection of early extracorporeal membrane oxygenation (ECMO) support for acute myocardial infarction with cardiogenic shock in pigs

Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page